Circio Holding Asa · OSL:CRNA
Circio Holding Asa — ESGCT 2026
18 slides from Circio Holding Asa's conference presentation, Oct 28, 2026
Slide 1: CircVec: A DNA Vector Platform Harnessing Intracellular Circular RNA Biogenesis for Next-Generation T-Cell Therapies
CircVec: A DNA Vector Platform Harnessing Intracellular Circular RNA Biogenesis for Next-Generation T-Cell Therapies Dr Thomas Hansen, CTO ESGCT, 2026
Slide 2: Disclaimer: Conflict of Interest & Employment Disclosure
Disclaimer Conflict of Interest & Employment Disclosure The speaker is a full-time employee and corporate executive at Circio and holds material equity, including stock options and shares, in the company. The scientific research, data, and viewpoints presented during this session are intrinsically l
Slide 3: Circio's unique and proprietary circRNA-based gene expression platform technology
Circio´s unique and proprietary circRNA- circVec based gene expression platform technology Viral or DNA vector mVec - standard circVec - proprietary mRNA approach circRNA approach ??? . . 75x prolonged An half-life vs. mRNA RNA Up to 60x enhanced Protein protein expression 3
Slide 4: Optimizing circular RNA-based gene expression: circVec construct design and evolution from Gen 1 to 4
Optimizing circular RNA-based gene expression: circVec construct design and evolution from Gen 1 → 4 The circVec evolution circVec protein quantification, Western blot ~36x ~1.5x ~4x ~2x ~40x increase for ~3x circVec 4.x vs. 1.1 State-of-the art in literature 4
Slide 5: Bioinformatic simulation demonstrating circRNA accumulation over time
Bioinformatic simulation demonstrating circRNA accumulation over time - driving increased expression Accumulation phase mRNA circVec Peak circRNA mVec Peak 5
Slide 6: In vivo validation of bioinformatic simulation: 75x prolonged RNA half-life
In vivo validation of bioinformatic simulation: 75x prolonged RNA half-life drives enhanced and durable gene expression Intramuscular DNA injection, Longitudinal IVIS analysis Inferred RNA half-life, Inferred peak expression, MCMC1 MCMC1 mVec circVec 38d Absolute luminescence, IVIS quantification ov
Slide 7: Circio is deploying the circVec platform for next generation gene and cell therapies
Circio is deploying the circVec platform for development of next generation gene and cell therapies Technical In vitro In vivo In vivo disease IND concept PoC technical PoC model enabling Heart, eye and CNS Genetic cardiomyopathy Enhanced, safer and lower Ophthalmology cost AAV gene therapy Research
Slide 8: 40-fold enhanced expression in heart for circVec-AAV vs. conventional mRNA-based AAV
40-fold enhanced expression in heart for circVec-AAV vs. conventional mRNA-based AAV AAV-mVec AAV-circVec 2.1 AAV-circVec 3.2 Gene expression quantification, f-luc IVIS signal D10 17 28 51 71 D10 17 28 51 71 D10 17 28 51 71 +40x gene expression Heart region 40x increased signal vs mVec 8 Systemic de
Slide 9: circVec increases heart penetrance and reduces cellular stress response vs. conventional AAV
circVec increases heart penetrance and reduces cellular stress response vs. conventional AAV Increased RNA penetrance in heart, Reduced stress response, RNAscope analysis RNAseq analysis AAV9-cTnT-circVec3.2 Nuclei/Firefly transcript Toxicity from Impact on UPR pathway mVec 80% of heart cells p=0.00
Slide 10: circVec optimization for heart increases expression advantage to ~200-fold
circVec optimization for heart increases expression advantage to ~200-fold with 95% on-target specificity Enhancement of biogenesis in heart, Enhancement of translation in heart, Reduced off-target liver expression, In vivo heart luminescence In vivo heart luminescence Ex vivo luminescence circVec5.
Slide 11: Visit Circio posters for more information on the AAV programs
Visit CIRCIO posters for more information on the AAV programs Poster: P0089 Poster: P0604 Wednesday Thursday 1:30-3:30pm 2-4pm 11
Slide 12: Circio is deploying the circVec platform for next generation gene and cell therapies
Circio is deploying the circVec platform for development of next generation gene and cell therapies Technical In vitro In vivo In vivo disease IND concept PoC technical PoC model enabling Heart, eye and CNS genetic Genetic cardiomyopathy disease Enhanced, safer and lower Ophthalmology cost AAVs CNS
Slide 13: Non-viral circVec: LNP-formulated DNA for durable and repeat-dosable in vivo cell therapy
Non-viral circVec: LNP-formulated DNA for durable and repeat-dosable in vivo cell therapy Liver and spleen LNP-formulated RNA biogenesis and translation targeting DNA (not RNA!) circRNA or An mRNA DNA formulation LNP tropism Gene expression kinetics in target cells dsDNA (or ssDNA) in lipid Using sy
Slide 14: In vivo cell therapy: circVec expression duration up to 6 months vs. 2 weeks
In vivo cell therapy: circVec expression duration up to 6 months vs. 2 weeks for mVec LNP-mVec, luminescence LNP-circVec luminescence Systemic I.V. delivery, single dose on Day 0 Systemic I.V. delivery, single dose on Day 0 Mainly short-term liver expression No liver expression Accumulation in splee
Slide 15: Nucleofection of Jurkat T-cell line shows enhanced and prolonged expression from circVec
Nucleofection of Jurkat T-cell line in vitro shows enhanced and prolonged expression from circVec circVec expression temporal kinetics Signal distribution. tdTomato fluorescence at day 7 Vector-based expression of tdTomato in Jurkat after nucleofection of jurkat cells Enhanced and High dose prolonge
Slide 16: Systemic delivery of T-cell tropic LNP:circVec recapitulate spleen targeting at 10x reduced dose
Systemic delivery of T-cell tropic LNP:circVec recapitulate spleen targeting at 10x reduced dose LNP-mVec w/ T-cell tropic LNP* LNP-circVec w/ T-cell tropic LNP* Systemic delivery, three dose levels Systemic delivery, three dose levels 0.20mg/kg Spleen signal detectable at Day 7 for high dose only 0
Slide 17: Take home messages
Take home messages 1 2 Accumulation of circVec delivers high circRNA from circVec RNA penetrance in leads to higher steady heart at low dose state expression 3 4 circVec reduces circVec enables translational stress transient spleen and unwanted signal for 3+ months expression in liver
Slide 18: Acknowledgements – Circio R&D team in Stockholm
Acknowledgements – Circio R&D team in Stockholm €80 million Capital raised in 2026 to fuel the next phase of Circio R&D We’re hiring Scientists at all levels Victor Levitsky Mohamed Warsame Jiangnan Liu Eoghan O’Leary Fahima Akter Ola Melin Early-career Experienced Senior Juan Zhang Yaxin An Erik Wi